Drug, across the briefings
Navitoclax across 9 cancers
Navitoclax appears in 9 of the briefings; no FDA label names any of them.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Acute myeloid leukemia | approved on BCL2 | 4 | 2 | |
| Chronic lymphocytic leukemia | approved on BCL2 | 8 | 0 | |
| Chronic myeloid leukemia | approved on BCL2 | — | — | |
| Diffuse large B-cell lymphoma | approved on BCL2 | 1 | 0 | |
| Follicular lymphoma | approved on BCL2 | 1 | 0 | |
| Mantle cell lymphoma | approved on BCL2 | 2 | 1 | |
| Myelodysplastic syndromes | approved on BCL2 | 2 | 1 | |
| Small cell lung cancer | approved on BCL2 | 3 | 0 | |
| Waldenström macroglobulinaemia | approved on BCL2 | — | — |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.